Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer
2022 · JAMA Oncology · 88 citations
https://doi.org/10.1001/jamaoncol.2022.5143
Y
Ying Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
247
Papers
5.3K
Citations
38
h-index
76
i10-index
Ying Liu is an academic researcher from Heilongjiang University of Chinese Medicine. The author has contributed to research in topics: Immunotherapy and Immune Responses & Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research. The author has an h-index of 38, co-authored 210 publications.
ORCID: 0000-0002-8997-2257Papers by this author
worksControlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab
2010 · Molecular Therapy · 70 citations
https://doi.org/10.1038/mt.2010.256
Improved dissolution and bioavailability of silymarin delivered by a solid dispersion prepared using supercritical fluids
2014 · Asian Journal of Pharmaceutical Sciences · 57 citations
https://doi.org/10.1016/j.ajps.2014.12.001
Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis
2020 · Journal of Nanobiotechnology · 57 citations
https://doi.org/10.1186/s12951-020-00638-x
Acute Retinal Necrosis Associated with Pseudorabies Virus Infection: A Case Report and Literature Review
2023 · Ocular Immunology and Inflammation · 11 citations
https://doi.org/10.1080/09273948.2023.2181188
Body mass index trajectory from childhood to puberty and high blood pressure: the China Health and Nutrition Survey
2021 · BMJ Open · 9 citations
https://doi.org/10.1136/bmjopen-2021-055099
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat